Consensus conference on the use of drug eluting stents in coronary heart disease;Positionspapier zum Einsatz von Medikamente freisetzenden Stents bei Patienten mit koronarer Herzerkrankung

Zeitschrift fur Kardiologie

Volumn 93, Issue 5, 2004, Pages 416-422

  Mudra, H ^a   Bode, C ^b   Grube, E ^b   De Haan, F ^b   Levenson, B ^b   Schuler, G ^b   Silber, S ^b  

^a Municipal Hospitals of Munich   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DEXAMETHASONE; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

ARTERY OCCLUSION; CONFERENCE PAPER; DRUG ELUTING STENT; ECONOMIC ASPECT; HUMAN; ISCHEMIC HEART DISEASE; METHODOLOGY; PERCUTANEOUS CORONARY INTERVENTION; STENT;

BLOOD VESSEL PROSTHESIS; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; GERMANY; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; STENTS;

EID: 2942612638     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-004-0119-8     Document Type: Conference Paper

References (32)

1. Abizaid A, Chan C, Kaul U et al (2003) "Real world" evaluation of slow-release. Polymer-based, paclitaxel-eluting TAXUS stents in native coronary arteries: the WISDOM international registry Circulation 108(Suppl IV):IV-534A
2. Al Suwaidi J, Berger PB, Holmes DR Jr et al (2000) Coronary artery stents. JAMA 284:1828-1836
3. Bauters C, Hubert E, Prat A et al (1998) Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 31:1291-1298
4. Boy O, Behrenbeck DW, Breithardt G et al (2003) Perkutane transluminale Koronarangioplastie (PTCA). BQS Bundesgeschäftsstelle Qualitä tssicherung GmbH. www.bqs.-online.de. BQS- Qualitätsreport 2002. S 150-165
5. Bruckenberger E (2003) Herzbericht 2002. S 28. www.herzbericht.de
6. Cohen DJ, Bakhai A, Shi C et al (2003) Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: results from the randomized SIRIUS trial. J Am Coll Cardiol 41(Suppl A):32A
7. Colombo A, Drzewiecki J, Banning A et al (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788-794
8. De Scheerder I (2003) Vortrag auf dem TCT-Kongress. www.tctmd.com
9. Dietz R, Silber S, Baumgart D et al (2001) Positionspapier zur intrakoronaren Brachytherapie. Z Kardiol 90: 875-880
10. Gershlick AH, de Scheerder I, Chevalier B et al (2001) Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (EvaLUation of pacliTaxel Eluting Stent) trial Circulation. 104(Suppl II):II-416A
11. Gershlick AH (2003) Nine-month subgroup analysis of the E-SIRIUS trial: diabetic vs. non-diabetic patients. Circulation 108(Suppl IV):IV-701A
12. Guagliumi G, Sousa E, Urban P et al (2003) Sirolimus-eluting stent in routine clinical practise: a 6-month follow-up report from the international e-CYPHER registry. Circulation 108 (Suppl IV):IV-534A
13. Hamm CW, Schneider S, Senges J (2003) Initial results of the German drug-eluting stent registry. Circulation 108(Suppl IV):IV-533A
14. Kastrati A, Schömig A, Elezi S et al (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428-1436
15. Kereiakes D, Moses JW, Leon MB et al (2003) Durable clinical benefit following CYPHER coronary stent deployment: SIRIUS study 2-year results. Circulation 108(Suppl IV):IV-532A
16. Lemos PA, Lee C, Degertekin M et al (2002) Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 41:2093-2099
17. Lemos PA, Serruys PW, van Domburg RT et al (2004) Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world". The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109:190-195
18. Levenson B (2003) Positionspapier zum Einsatz von beschichteten Stents (DES) bei perkutanen Koronarinterventionen bei Patienten mit koronarer Herzerkrankung. Z Kardiol 92:606-612
19. Morice MC, Serruys PW, Sousa JE et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
20. Morice MC, Serruys PW, Costatini C et al (2003) Two-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting BX VELOCITYTM stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 41(Suppl A):32A
21. Moses JW, Leon MB, Popma JJ et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
22. National Institute for Clinical Excellence (2003) Guidance on the use of coronary artery stents. www.nice. org.uk. Technology Appraisal 71
23. Schofer J, Schlüter M, Gershlick AH et al (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) Lancet 362:1093-1099
24. Silber S (2003) Paclitaxel-eluting stents: are the all equal? An analysis of six randomized controlled trials in de novo lesions of 3319 patients. J Interv Cardiol 16:485-490
25. Silber S, Albertson P, Aviles FF et al (2004) European guidelines for percutaneous coronary interventions (PCI) Eur Heart J (im Druck)
26. Sousa JE, Costa MA, Abizaid AC et al (2001) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104:2007-2011
27. Sousa JE, Serruys PW, Costa MA (2003) New frontiers in cardiology. Drug eluting stents: Part I. Circulation 107:2274-2279
28. Sousa JE, Serruys PW, Costa MA (2003) New frontiers in cardiology. Drug eluting stents: Part II. Circulation 107:2383-2389
29. Stone GW, Ellis SG, Cox DA et al (2003) A polymer-based. Paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231
30. Stone GW, Ellis SG, Cox DA et al (2003) The pivotal US study of the slow-rate release polymer-based Paclitaxel-eluting TAXUS stent in patients with de novo coronary lesions: 1-year clinical results of the TAXUS-IV trial. Circulation 108(Suppl IV):IV-533
31. Virmani R, Liistro F, Stankovic G et al (2003) Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106: 2649-2651
32. Zahn R, Hamm CW, Zeymer U et al (2004) Aktuelle Indikationsstellung und Sicherheit beim Einsatz des koronaren Sirolimus-Stents im klinischen Alltag in Deutschland. Z Kardiol (im Druck)